ChinaDrugStatus

Mazdutide

玛仕度肽
Brand: Xinermei / 信尔美·Endocrinology / Metabolic·Last verified 2026-11-20

Dual GCG/GLP-1 receptor agonist approved by NMPA for chronic weight management (Jun 2025) and T2D (Sep 2025); added to 2026 NRDL restricted to adult T2D.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字H20250036, 国药准字H20250037, 国药准字H20250038
Initial Approval Date
Jun 24, 2025
Notice Published
Jun 30, 2025
MAH
Innovent Biologics (Suzhou) Co., Ltd. (信达生物制药(苏州)有限公司)
Approved Scope
3 initial presentation(s) & 1 supplemental event(s) verified — see table below.

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #30 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Restricted to adults with Type 2 Diabetes mellitus.
限成人2型糖尿病患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

4 verified NMPA records
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字H20250036
Injection (注射液)
0.5ml:2mg / 4mg / 6mg
Supplemental Indication

Glycemic control in adults with Type 2 Diabetes mellitus (monotherapy or in combination with oral antidiabetic agents); covers H20250036 / H20250037 / H20250038.

本品适用于成人2型糖尿病患者的血糖控制(单药治疗或联合二甲双胍等口服降糖药)。

Approved: 2025-09-16
Innovent Biologics (Suzhou) Co., Ltd.
国药准字H20250036
Injection (注射液)
0.5ml:2mg
Initial Approval

Chronic weight management in adults as an adjunct to diet and physical activity (initial BMI ≥ 28 kg/m² obesity, or BMI ≥ 24 kg/m² overweight with at least one weight-related comorbidity).

本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

Approved: 2025-06-24
Published: 2025-06-30
Innovent Biologics (Suzhou) Co., Ltd.
国药准字H20250037
Injection (注射液)
0.5ml:4mg
Initial Approval

Chronic weight management in adults (4 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).

本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

Approved: 2025-06-24
Published: 2025-06-30
Innovent Biologics (Suzhou) Co., Ltd.
国药准字H20250038
Injection (注射液)
0.5ml:6mg
Initial Approval

Chronic weight management in adults (6 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).

本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

Approved: 2025-06-24
Published: 2025-06-30
Innovent Biologics (Suzhou) Co., Ltd.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Added to Negotiated List

    Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed).

    Chinese original: 新增纳入2026版谈判药品第30项(乙类,支付标准*),限成人2型糖尿病患者;协议期2027-01-01至2028-12-31。

    NHSA · PDF p.119Verified 2026-11-20
  2. (2025-09-16)NMPA Approval

    NMPA Supplemental Indication Approval (国药准字H20250036 · 0.5ml:2mg / 4mg / 6mg)

    Glycemic control in adults with Type 2 Diabetes mellitus (monotherapy or in combination with oral antidiabetic agents); covers H20250036 / H20250037 / H20250038.

    Chinese original: 本品适用于成人2型糖尿病患者的血糖控制(单药治疗或联合二甲双胍等口服降糖药)。

    MAH · PDF p.3 (T2D Label)Verified 2026-11-20
  3. (2025-06-24)NMPA Approval· Notice published: Jun 30, 2025

    NMPA Initial Marketing Approval (国药准字H20250036 · 0.5ml:2mg)

    Chronic weight management in adults as an adjunct to diet and physical activity (initial BMI ≥ 28 kg/m² obesity, or BMI ≥ 24 kg/m² overweight with at least one weight-related comorbidity).

    Chinese original: 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

  4. (2025-06-24)NMPA Approval· Notice published: Jun 30, 2025

    NMPA Initial Marketing Approval (国药准字H20250037 · 0.5ml:4mg)

    Chronic weight management in adults (4 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).

    Chinese original: 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

  5. (2025-06-24)NMPA Approval· Notice published: Jun 30, 2025

    NMPA Initial Marketing Approval (国药准字H20250038 · 0.5ml:6mg)

    Chronic weight management in adults (6 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).

    Chinese original: 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

Mazdutide Injectiondosage name(MAH)
玛仕度肽注射液dosage name(NHSA)
IBI362code(WHO)
LY3305677code(WHO)
信尔美brand zh(MAH)

Primary Sources for This Record